Particle.news
Get it on Google Play
Download on the App Store
30 ARTICLES
·
2h ago

FDA Requires Vision‑Loss Warnings for All GLP‑1 Drugs

The move forces class‑wide label changes after the FDA's review found a small measurable rise in rare optic‑nerve events.

The FDA is now requiring the makers of GLP-1 drugs like Ozempic and Wegovy to include a label warning of an increased risk to develop a serious eye condition. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. 
Image
Ozempic may cause rare blindness (Credits: iStock)
Signage outside the US Food and Drug Administration headquarters in Silver Spring, Maryland, US, on Tuesday, April 28, 2026.

Overview

  • The FDA announced Monday that makers must add a warning about non‑arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of every GLP‑1 product label.
  • The agency reviewed 126 randomized trials covering about 134,000 people and identified 15 probable NAION events, with 10 cases in GLP‑1 arms and five in control arms, equal to roughly 6.4 versus 3.8 cases per 100,000 person‑years.
  • Regulators stressed the evidence does not prove causation and no biological mechanism has been established while advising urgent ophthalmologic evaluation for anyone with sudden visual changes.
  • Manufacturers including Novo Nordisk and Eli Lilly say the data do not establish a direct link and they are reviewing the requirement as thousands of lawsuits alleging vision loss continue in U.S. courts.
  • Clinicians are told to discuss risks with patients, consider stopping treatment case‑by‑case if NAION is suspected, and watch for follow‑up studies and safety reports that could clarify whether risk differs by specific GLP‑1 drugs.